98 related articles for article (PubMed ID: 19956850)
1. Pharmacokinetics, biodistribution and metabolism of a novel selective androgen receptor modulator designed for prostate cancer imaging.
Yang J; Wu Z; Wu D; Darby MV; Hong SS; Miller DD; Dalton JT
Int J Oncol; 2010 Jan; 36(1):213-22. PubMed ID: 19956850
[TBL] [Abstract][Full Text] [Related]
2. In vivo metabolism and final disposition of a novel nonsteroidal androgen in rats and dogs.
Perera MA; Yin D; Wu D; Chan KK; Miller DD; Dalton J
Drug Metab Dispos; 2006 Oct; 34(10):1713-21. PubMed ID: 16815963
[TBL] [Abstract][Full Text] [Related]
3. 7alpha-Iodo and 7alpha-fluoro steroids as androgen receptor-mediated imaging agents.
Labaree DC; Hoyte RM; Nazareth LV; Weigel NL; Hochberg RB
J Med Chem; 1999 Jun; 42(11):2021-34. PubMed ID: 10354410
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers.
Ko YJ; Devi GR; London CA; Kayas A; Reddy MT; Iversen PL; Bubley GJ; Balk SP
J Urol; 2004 Sep; 172(3):1140-4. PubMed ID: 15311058
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts.
Chiu FL; Lin JK
Prostate; 2008 Jan; 68(1):61-71. PubMed ID: 18008333
[TBL] [Abstract][Full Text] [Related]
7. Androgen axis in prostate cancer.
Culig Z; Bartsch G
J Cell Biochem; 2006 Oct; 99(2):373-81. PubMed ID: 16598769
[TBL] [Abstract][Full Text] [Related]
8. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells.
Sadar MD; Gleave ME
Cancer Res; 2000 Oct; 60(20):5825-31. PubMed ID: 11059779
[TBL] [Abstract][Full Text] [Related]
9. Preclinical pharmacology of a nonsteroidal ligand for androgen receptor-mediated imaging of prostate cancer.
Yang J; Bohl CE; Nair VA; Mustafa SM; Hong SS; Miller DD; Dalton JT
J Pharmacol Exp Ther; 2006 Apr; 317(1):402-8. PubMed ID: 16434567
[TBL] [Abstract][Full Text] [Related]
10. Ectopic expression of the amino-terminal peptide of androgen receptor leads to androgen receptor dysfunction and inhibition of androgen receptor-mediated prostate cancer growth.
Minamiguchi K; Kawada M; Ohba S; Takamoto K; Ishizuka M
Mol Cell Endocrinol; 2004 Feb; 214(1-2):175-87. PubMed ID: 15062556
[TBL] [Abstract][Full Text] [Related]
11. A differential ligand-mediated response of green fluorescent protein-tagged androgen receptor in living prostate cancer and non-prostate cancer cell lines.
Nakauchi H; Matsuda K; Ochiai I; Kawauchi A; Mizutani Y; Miki T; Kawata M
J Histochem Cytochem; 2007 Jun; 55(6):535-44. PubMed ID: 17312014
[TBL] [Abstract][Full Text] [Related]
12. Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis.
Mulholland DJ; Read JT; Rennie PS; Cox ME; Nelson CC
Oncogene; 2003 Aug; 22(36):5602-13. PubMed ID: 12944908
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and metabolism of a selective androgen receptor modulator in rats: implication of molecular properties and intensive metabolic profile to investigate ideal pharmacokinetic characteristics of a propanamide in preclinical study.
Wu D; Wu Z; Yang J; Nair VA; Miller DD; Dalton JT
Drug Metab Dispos; 2006 Mar; 34(3):483-94. PubMed ID: 16381665
[TBL] [Abstract][Full Text] [Related]
15. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
16. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
[TBL] [Abstract][Full Text] [Related]
17. The role of the androgen receptor in the development and progression of prostate cancer.
Jenster G
Semin Oncol; 1999 Aug; 26(4):407-21. PubMed ID: 10482183
[TBL] [Abstract][Full Text] [Related]
18. Xenoestrogen action in prostate cancer: pleiotropic effects dependent on androgen receptor status.
Wetherill YB; Fisher NL; Staubach A; Danielsen M; de Vere White RW; Knudsen KE
Cancer Res; 2005 Jan; 65(1):54-65. PubMed ID: 15665279
[TBL] [Abstract][Full Text] [Related]
19. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
Yang Q; Titus MA; Fung KM; Lin HK
J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
[TBL] [Abstract][Full Text] [Related]
20. Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer.
Jackson KM; Frazier MC; Harris WB
Anticancer Res; 2007; 27(3B):1483-8. PubMed ID: 17595765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]